** Shares of drug developer Silexion Therapeutics SLXN.O rise ~125% to $1.30 premarket
** SLXN says preclinical trials of its cancer treatment, SIL-204, shows significant reduction in tumor growth in pancreatic cancer models
** SIL-204 reduced tumor growth by 50% and showed complete necrosis in 50% of tumors in some trials
** Says SIL-204 was effective in inhibiting key cancer-causing KRAS mutations and maintained effective drug levels in the body for over 56 days
** SLXN fell 88.4% in 2024, since its Nasdaq debut on Aug. 16, 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.